Aug. 1 at 12:36 PM
$ALLO As of August 1, 2025, Allogene has discontinued the lymphodepletion arm combining fludarabine/cyclophosphamide (FC) with ALLO-647 following a Grade 5 adverse event involving hepatic failure due to disseminated adenovirus infection in that arm. The decision was made in consultation with the trial’s DSMB, steering committee, and the FDA. ([turn0search0]; [turn0search4])
